Creso Pharma Limited welcomed the introduction of over-the-counter sales of low-dose cannabidiol (CBD) products in Australian pharmacies from 1 February 2021. The sale of low-dose CBD products was made possible following a decision from the Therapeutic Goods Administration (TGA) to down-schedule low dose cannabidiol (CBD) preparations from Schedule 4 (Prescription Medicine) to Schedule 3 (Pharmacist Only Medicine). The decision has led to CBD products containing up to a maximum of 150mg/day, for use in adults that have been approved by the TGA, to be sold by a pharmacist to customers without a prescription. Products must be approved by the TGA and included on the Australian Register of Therapeutic Goods (ARTG). This is a major development for the Australian medicinal cannabis industry and highlights a large market Highway, | Nedlands, WA, 6009 | Australia 145 Stirlingopportunity that is estimated to exceed $200 million per annum. Creso Pharma is very well placed to capitalise on the growing market opportunity in Australia. The Company has an existing portfolio of CBD products being actively sold in several countries globally, with its CannaQIX® 50 product already available in Australia via prescription, under the LozaCan brand.